ALPN - Alpine Immune Sciences Analysts Boost Their Forecasts After Q4 Earnings | Benzinga
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) reported better-than-expected fourth-quarter financial results.
Alpine Immune Sciences posted GAAP earnings of 15 cents per share, versus market estimates for a loss of 29 cents per share. The company’s quarterly sales came in at $30.853 million, compared to expectations of $9.104 million, according to data from Benzinga Pro.
"2023 was a transformational year for Alpine, with initial IgA nephropathy (IgAN) data presented at the American Society of Nephrology Kidney Week 2023 suggesting a best-in-class profile for povetacicept, our next-generation dual BAFF/APRIL inhibitor. With our encouraging data set in IgAN, convenient once monthly ...